{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T17:45:50Z","timestamp":1702403150237},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Trifluridine\/tipiracil increases overall survival (OS) in patients with refractory, metastatic colorectal cancer (mCRC). A post hoc exploratory analysis of the RECOURSE randomized clinical trial (RCT) established two categories, a good prognosis corresponding to subjects having a low tumor burden and indolent disease. Other models in refractory mCRC are the FAS-CORRECT and Colon Life nomogram. The main objective was to externally validate the prognostic factors of the RECOURSE and FAS-CORRECT trials, and the Colon Life nomogram in a multicenter, real-world series of mCRC treated in 3rd and successive lines with trifluridine\/tipiracil. The secondary aim was to develop an OS predictive model, TAS-RECOSMO. Between 2016 and 2019, 244 patients were recruited. Median OS was 8.15 vs 8.12\u00a0months for the poor (85% of the subjects) and good (15%) prognosis groups from the RESOURCE trial, respectively, log-rank p\u2009=\u20090.9. The most common grade 3\u20134 toxicities were neutropenia (17%), asthenia (6%), and anemia (5%). The AFT lognormal model TAS-RECOSMO included six variables: ECOG-PS, KRAS\/NRAS\/BRAF mutation status, time between diagnosis of metastasis and beginning of trifluridine\/tipiracil, NLR, CEA, and alkaline phosphatase. The model\u2019s bootstrapped bias-corrected c-index was 0.682 (95% CI, 0.636\u20130.722). The factors from the Colon Life model, FAS-CORRECT, and RECOURSE displayed a c-index of 0.690, 0.630, and 0.507, respectively. TAS-RECOSMO, FAS-CORRECT, and the Colon Life nomogram appear to predict OS in patients with refractory mCCR who begin trifluridine\/tipiracil treatment in the real world. The prognostic groups of the RECOURCE RCT were unable to capture the situation of real-world subjects treated with trifluridine\/tipiracil in this series.<\/jats:p>","DOI":"10.1038\/s41598-021-93732-5","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T10:03:29Z","timestamp":1626084209000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine\/tipiracil: real-world vs clinical trial data"],"prefix":"10.1038","volume":"11","author":[{"given":"Ana","family":"Fern\u00e1ndez Montes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Carmona-Bayonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Jimenez-Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"V\u00e1zquez Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nieves","family":"Martinez Lago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Covela R\u00faa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00eda","family":"Cousillas Casti\u00f1eiras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Gonzalez Villarroel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"De la C\u00e1mara G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Carlos M\u00e9ndez","family":"M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Carriles Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Sanchez C\u00e1novas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Garcia Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"key":"93732_CR1","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.2147\/CMAR.S213236","volume":"12","author":"M Lam","year":"2020","unstructured":"Lam, M. et al. Refractory metastatic colorectal cancer: current challenges and future prospects. Cancer Manag. Res. 12, 5819 (2020).","journal-title":"Cancer Manag. Res."},{"key":"93732_CR2","doi-asserted-by":"crossref","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. Mass Medical Soc; 2015;372:1909\u201319.","DOI":"10.1056\/NEJMoa1414325"},{"key":"93732_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejca.2017.10.009","volume":"90","author":"E Van Cutsem","year":"2018","unstructured":"Van Cutsem, E. et al. The subgroups of the phase III RECOURSE trial of trifluridine\/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur. J. Cancer. Elsevier 90, 63\u201372 (2018).","journal-title":"Eur. J. Cancer. Elsevier"},{"key":"93732_CR4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jamaoncol.2015.2378","volume":"1","author":"HG Prigerson","year":"2015","unstructured":"Prigerson, H. G. et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. American Medical Association 1, 778\u2013784 (2015).","journal-title":"JAMA Oncol. American Medical Association"},{"key":"93732_CR5","doi-asserted-by":"crossref","unstructured":"Tabernero J, Argiles G, Sobrero AF, Borg C, Ohtsu A, Mayer RJ, et al. Effect of trifluridine\/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis. ESMO open. BMJ Publishing Group Limited; 2020;5:e000752.","DOI":"10.1136\/esmoopen-2020-000752"},{"key":"93732_CR6","doi-asserted-by":"crossref","unstructured":"Andersen SE, Andersen IB, Jensen B V, Pfeiffer P, Ota T, Larsen JS. A systematic review of observational studies of trifluridine\/tipiracil (TAS-102) for metastatic colorectal cancer. Acta Oncol. (Madr). Taylor & Francis; 2019;58:1149\u201357.","DOI":"10.1080\/0284186X.2019.1605192"},{"key":"93732_CR7","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s10147-017-1220-0","volume":"23","author":"JJM Kwakman","year":"2018","unstructured":"Kwakman, J. J. M. et al. Feasibility and effectiveness of trifluridine\/tipiracil in metastatic colorectal cancer: real-life data from the Netherlands. Int. J. Clin. Oncol. Springer 23, 482\u2013489 (2018).","journal-title":"Int. J. Clin. Oncol. Springer"},{"key":"93732_CR8","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/annonc\/mdw627","volume":"28","author":"F Pietrantonio","year":"2017","unstructured":"Pietrantonio, F. et al. Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Ann. Oncol. Oxford University Press 28, 555\u2013561 (2017).","journal-title":"Ann. Oncol. Oxford University Press"},{"key":"93732_CR9","doi-asserted-by":"crossref","unstructured":"Pietrantonio F, Fuc\u00e0 G, Manca P, Pagani F, Raimondi A, Prisciandaro M, et al. Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial. Tumori J. SAGE Publications Sage UK: London, England; 2020;0300891620960808.","DOI":"10.1177\/0300891620960808"},{"key":"93732_CR10","doi-asserted-by":"crossref","unstructured":"Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer. BioMed Central; 2016;16:412.","DOI":"10.1186\/s12885-016-2559-8"},{"key":"93732_CR11","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez Montes A, L\u00f3pez L\u00f3pez C, Argil\u00e9s Mart\u00ednez G, P\u00e1ez L\u00f3pez D, L\u00f3pez Mu\u00f1oz AM, Garc\u00eda Paredes B, et al. Prognostic nomogram and patterns of use of FOLFIRI\u2010Aflibercept in advanced colorectal cancer: a real\u2010world data analysis. Oncologist. Wiley Online Library; 2019;24.","DOI":"10.1634\/theoncologist.2018-0824"},{"key":"93732_CR12","doi-asserted-by":"crossref","unstructured":"Carmona-Bayonas A, Jimenez-Fonseca P, Garrido M, Custodio A, Hernandez R, Lacalle A, et al. Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer. Thromb. Haemost. 2019;119.","DOI":"10.1055\/s-0039-1694012"},{"key":"93732_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis","author":"F Harrell","year":"2015","unstructured":"Harrell, F. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis 2nd edn. (Springer, 2015).","edition":"2"},{"key":"93732_CR14","first-page":"3","volume":"3","author":"FE Harrell Jr","year":"2006","unstructured":"Harrell, F. E. Jr. & Dupont, M. C. The Hmisc package. R Packag. version. 3, 3 (2006).","journal-title":"R Packag. version."},{"key":"93732_CR15","unstructured":"Harrell Jr F, Frank E, Maintaner Frank E. Package \u2018rms\u2019. [Internet]. 2015 [cited 2020 Jan 1]. p. 229. Available from: http:\/\/cran.r-project.org\/web\/packages\/rms\/index.html."},{"key":"93732_CR16","unstructured":"Breheny P, Burchett W. Visualization of regression models using visreg. R Packag. 2013;1\u201315."},{"key":"93732_CR17","doi-asserted-by":"crossref","unstructured":"Persaud N, Mamdani MM. External validity: the neglected dimension in evidence ranking. J. Eval. Clin. Pract. Wiley Online Library; 2006;12:450\u20133.","DOI":"10.1111\/j.1365-2753.2006.00730.x"},{"key":"93732_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/01.nmd.0000110279.23893.82","volume":"192","author":"M Zimmerman","year":"2004","unstructured":"Zimmerman, M., Chelminski, I. & Posternak, M. A. Exclusion criteria used in antidepressant efficacy trials: consistency across studies and representativeness of samples included. J. Nerv. Ment. Dis. LWW 192, 87\u201394 (2004).","journal-title":"J. Nerv. Ment. Dis. LWW"},{"key":"93732_CR19","doi-asserted-by":"crossref","unstructured":"Cicero G, Addeo R, De Luca R, Re G Lo, Gulotta L, Marchesa P, et al. TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study. Drugs Context. BioExcel Publishing Ltd; 2020;9.","DOI":"10.7573\/dic.2020-6-3"},{"key":"93732_CR20","doi-asserted-by":"crossref","unstructured":"Wallander M, Rolander B, \u00c5vall-Lundqvist E, Elander NO. Real world aspects of palliative trifluridine plus tiperacil (TAS-102) in refractory metastatic colorectal cancer. J. Gastrointest. Oncol. AME Publications; 2020;11:616.","DOI":"10.21037\/jgo-20-43"},{"key":"93732_CR21","doi-asserted-by":"crossref","unstructured":"Bachet J-B, Wyrwicz L, Price T, Cremolini C, Phelip J-M, Portales F, et al. Safety, efficacy and patient-reported outcomes with trifluridine\/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. ESMO Open. BMJ Publishing Group Limited; 2020;5:e000698.","DOI":"10.1136\/esmoopen-2020-000698"},{"key":"93732_CR22","doi-asserted-by":"crossref","unstructured":"Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, et al. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine\/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. Int. J. Clin. Oncol. Springer; 2019;1\u20138.","DOI":"10.1007\/s10147-019-01600-0"},{"key":"93732_CR23","doi-asserted-by":"crossref","unstructured":"Kotani D, Kuboki Y, Horasawa S, Kaneko A, Nakamura Y, Kawazoe A, et al. Retrospective cohort study of trifluridine\/tipiracil (TAS-102) plus bevacizumab versus trifluridine\/tipiracil monotherapy for metastatic colorectal cancer. BMC Cancer. Springer; 2019;19:1253.","DOI":"10.1186\/s12885-019-6475-6"},{"key":"93732_CR24","doi-asserted-by":"crossref","unstructured":"Altman DG, Royston P. The cost of dichotomising continuous variables. Bmj. British Medical Journal Publishing Group; 2006;332:1080.","DOI":"10.1136\/bmj.332.7549.1080"},{"key":"93732_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12094-019-02130-x","volume":"22","author":"AF Montes","year":"2020","unstructured":"Montes, A. F. et al. Efficacy and safety of trifluridine\/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. Clin. Transl. Oncol. Springer 22, 351\u2013359 (2020).","journal-title":"Clin. Transl. Oncol. Springer"},{"key":"93732_CR26","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1093\/annonc\/mdy004","volume":"29","author":"E Dell\u2019Aquila","year":"2018","unstructured":"Dell\u2019Aquila, E. et al. Prognostic and predictive role of neutrophil\/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. Ann. Oncol. Oxford University Press 29, 924\u2013930 (2018).","journal-title":"Ann. Oncol. Oxford University Press"},{"key":"93732_CR27","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/bjc.2017.122","volume":"116","author":"A Custodio","year":"2017","unstructured":"Custodio, A. et al. Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: A multicenter prospective study in the era of trastuzumab. Br. J. Cancer. 116, 1526\u20131535 (2017).","journal-title":"Br. J. Cancer."},{"key":"93732_CR28","doi-asserted-by":"crossref","unstructured":"Nakashima M, Takeuchi M, Kawakami K. Effectiveness and safety of regorafenib vs. trifluridine\/tipiracil in unresectable colorectal cancer: A retrospective cohort study1. Clin. Colorectal Cancer. Elsevier; 2020;","DOI":"10.1016\/j.clcc.2020.05.003"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93732-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93732-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93732-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T10:58:05Z","timestamp":1670065085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93732-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["93732"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-93732-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]},"assertion":[{"value":"14 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14321"}}